PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

NCT ID: NCT06900218

Last Updated: 2025-04-02

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 664 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-01
• Study Completion Date: 2033-05-01

Brief Summary

This study will enroll 664 patients who had completed induction chemotherapy combined with the PD-1 antibody sintilimab treatment followed by concurrent cisplatin-based chemoradiotherapy (no concurrent sintiliamb). Patients will be randomly divided into two groups. One group will receive 9 cycles of sintilimab therapy, while the other group will receive an additional year of capecitabine chemotherapy on top of the sintilimab treatment. The primary endpoints will be event-free survival and overall survival.

Conditions

Nasopharyngeal Carcinoma (NPC)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Sintilimab Combined with Capecitabine

Group Type: EXPERIMENTAL

Sintilimab

Intervention Type: DRUG

Sintilimab 200 mg, administered on Day 1, every 3 weeks for a total of 9 cycles

Capecitabine

Intervention Type: DRUG

Capecitabine 650 mg/m², taken orally twice daily, continuously from Day 1 to Day 21, every 3 weeks, for a maximum of 1 year.

Sintilimab

Group Type: ACTIVE_COMPARATOR

Sintilimab

Intervention Type: DRUG

Sintilimab 200 mg, administered on Day 1, every 3 weeks for a total of 9 cycles

Interventions

Sintilimab

Sintilimab 200 mg, administered on Day 1, every 3 weeks for a total of 9 cycles

Intervention Type: DRUG

Capecitabine

Capecitabine 650 mg/m², taken orally twice daily, continuously from Day 1 to Day 21, every 3 weeks, for a maximum of 1 year.

Intervention Type: DRUG

Other Intervention Names

IBI308; PD-1 antibody

Eligibility Criteria

Inclusion Criteria

• Aged 18 to 65 years.
• ECOG performance status of 0-1.
• Newly diagnosed nasopharyngeal carcinoma confirmed by pathological examination of the primary lesion.
• Staging is classified as T4N1M0 or T1-4N2-3M0 according to the 9th Edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system.
• Must have received recommended radical radiochemotherapy and sintilimab: 3 cycles of gemcitabine combined with cisplatin and Sintilimab; radical intensity-modulated radiotherapy with a total dose of 6,996 cGy over 33 fractions, concurrently receiving 2 cycles of cisplatin at 100 mg/m².
• Completed the last radiation treatment within 2 weeks before randomization.
• neutrophil count ≥ 1.5 × 10⁹/L, hemoglobin concentration ≥ 90g/L, platelet count ≥ 100 × 10⁹/L.
• Total bilirubin ≤ 1.5 times the upper limit of normal; AST and/or ALT ≤ 2.5 times the upper limit of normal; creatinine clearance ≥ 50 mL/min.
• Participants must sign an informed consent form and be willing and able to comply with the study's visit, treatment regimen, laboratory tests, and other requirements.
• Female participants of childbearing potential and male participants with fertile partners must agree to use reliable contraception (such as condoms, or physician-recommended contraceptive pills) from screening to one year post-treatment.

Exclusion Criteria

• Active, known, or suspected autoimmune diseases. Participants with Type I diabetes, hypothyroidism requiring only hormone replacement therapy, or skin diseases (e.g., vitiligo, psoriasis, or alopecia) that do not require systemic treatment can be included.
• Severe immune-related adverse events that occurred during the initial Sintilimab induction treatment, as judged by the investigator, preventing continued adjuvant treatment with Sintilimab.
• Received any non-diagnostic surgeries or other targeted, immune, or biological therapies for nasopharyngeal carcinoma except the recommended radiochemotherapy and Sintilimab treatment before randomization.
• factors affecting oral medication (e.g., swallowing difficulties, chronic diarrhea, bowel obstruction).
• Disease progression post-radical radiotherapy.
• Positive HBsAg with HBV DNA > 200 IU/ml or 1000 copies/ml.
• Positive HCV antibody.
• Received systemic corticosteroids or other immunosuppressive therapy at equivalent doses > 10 mg of prednisone/day within 28 days before informed consent. Patients on systemic corticosteroids ≤ 10 mg of prednisone/day or inhaled/topical corticosteroids can be included. Using corticosteroids to manage or prevent treatment-related toxicity is permissible for inclusion.
• Active tuberculosis. Patients with active tuberculosis within the past year are excluded, even if treated; patients with a history of active tuberculosis over one year ago are also excluded unless they can prove they have undergone standard anti-tuberculosis therapy.
• History of interstitial lung disease.
• Received a live vaccine within 30 days before informed consent or is scheduled to receive one.
• HIV infection.
• Current or previous malignancies, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or papillary thyroid carcinoma.
• Pregnant or breastfeeding women; pregnancy tests should be considered for sexually active women of childbearing potential.
• Other diseases or conditions assessed by the investigator that may jeopardize patient safety or compliance, such as unstable cardiac diseases, renal diseases, chronic hepatitis, poorly controlled diabetes, psychiatric disorders, severely abnormal laboratory results, or other family or social high-risk factors.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Jun Ma, MD

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Sun Yat-sen University Cancer Center

Guangzhou, China, China

Countries

China

Central Contacts

Xu Liu, MD

Role: CONTACT

liux325@mail.sysu.edu.cn

8687343500

Facility Contacts

Xu Liu, MD

Role: primary

liux325@mail.sysu.edu.cn

8687343500

Other Identifiers

2025-FXY-001-FLK

Identifier Type: -

Identifier Source: org_study_id